Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study

Nivolumab is one of the standard therapy for previously treated advanced non-small-cell lung cancer (NSCLC) [1]. Durable responses are observed in NSCLC patients treated with nivolumab, but there are fewer than half of patients who will benefit [1].

http://ift.tt/2sroOnm